PIA
CHRS icon

Phoenix Investment Adviser’s Coherus Oncology CHRS Stock Holding History

Phoenix Investment Adviser’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,500
Closed -$77K – 33
2019
Q2 		$77K Buy
+3,500
New +$60.8K 0.14% 30

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Phoenix Investment Adviser's CHRS Position: Q3 2019 in Review

Phoenix Investment Adviser sold out of Coherus Oncology (CHRS) in Q3 2019, closing a stake of 3,500 shares — an estimated $77K sold.

Phoenix Investment Adviser first reported a position in CHRS in Q2 2019 and held it in 1 quarter. The position peaked at $77K in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

  • Phoenix Investment Adviser reported no remaining Coherus Oncology position as of Q3 2019 after selling out during the quarter.
  • Phoenix Investment Adviser sold 3,500 Coherus Oncology shares in Q3 2019, an estimated $77K.
  • Phoenix Investment Adviser first reported a position in Coherus Oncology in Q2 2019 and held it in 1 quarter.
  • Phoenix Investment Adviser's Coherus Oncology position peaked at $77K in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Phoenix Investment Adviser's 13F filing for Q3 2019, filed 13 Nov 2019.